161 related articles for article (PubMed ID: 24817037)
1. HOXA9 inhibits migration of lung cancer cells and its hypermethylation is associated with recurrence in non-small cell lung cancer.
Hwang JA; Lee BB; Kim Y; Hong SH; Kim YH; Han J; Shim YM; Yoon CY; Lee YS; Kim DH
Mol Carcinog; 2015 Jun; 54 Suppl 1():E72-80. PubMed ID: 24817037
[TBL] [Abstract][Full Text] [Related]
2. HOXA11 hypermethylation is associated with progression of non-small cell lung cancer.
Hwang JA; Lee BB; Kim Y; Park SE; Heo K; Hong SH; Kim YH; Han J; Shim YM; Lee YS; Kim DH
Oncotarget; 2013 Dec; 4(12):2317-25. PubMed ID: 24259349
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic inactivation of heparan sulfate (glucosamine) 3-O-sulfotransferase 2 in lung cancer and its role in tumorigenesis.
Hwang JA; Kim Y; Hong SH; Lee J; Cho YG; Han JY; Kim YH; Han J; Shim YM; Lee YS; Kim DH
PLoS One; 2013; 8(11):e79634. PubMed ID: 24265783
[TBL] [Abstract][Full Text] [Related]
4. Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer.
Ko E; Lee BB; Kim Y; Lee EJ; Cho EY; Han J; Shim YM; Park J; Kim DH
Clin Cancer Res; 2013 Mar; 19(5):1204-12. PubMed ID: 23319821
[TBL] [Abstract][Full Text] [Related]
5. Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer.
Wang G; Hu X; Lu C; Su C; Luo S; Luo ZW
Lung Cancer; 2008 Nov; 62(2):162-72. PubMed ID: 18468719
[TBL] [Abstract][Full Text] [Related]
6. Promoter methylation-mediated silencing of β-catenin enhances invasiveness of non-small cell lung cancer and predicts adverse prognosis.
Miao Y; Wang L; Zhang X; Xu X; Jiang G; Fan C; Liu Y; Lin X; Yu J; Zhang Y; Wang E
PLoS One; 2014; 9(11):e112258. PubMed ID: 25396757
[TBL] [Abstract][Full Text] [Related]
7. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
Kim JS; Kim JW; Han J; Shim YM; Park J; Kim DH
Cancer Res; 2006 Apr; 66(8):4049-54. PubMed ID: 16618724
[TBL] [Abstract][Full Text] [Related]
8. Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer.
Zhang Y; Miao Y; Yi J; Wang R; Chen L
Clin Lung Cancer; 2010 Jul; 11(4):264-70. PubMed ID: 20630829
[TBL] [Abstract][Full Text] [Related]
9. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer.
Chang YS; Wang L; Liu D; Mao L; Hong WK; Khuri FR; Lee HY
Clin Cancer Res; 2002 Dec; 8(12):3669-75. PubMed ID: 12473575
[TBL] [Abstract][Full Text] [Related]
10. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung.
Kim JS; Kim H; Shim YM; Han J; Park J; Kim DH
Carcinogenesis; 2004 Nov; 25(11):2165-71. PubMed ID: 15231689
[TBL] [Abstract][Full Text] [Related]
11. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?
Kim YT; Lee SH; Sung SW; Kim JH
Ann Thorac Surg; 2005 Apr; 79(4):1180-8; discussion 1180-8. PubMed ID: 15797047
[TBL] [Abstract][Full Text] [Related]
12. Methylated DLX4 Predicts Response to Pathologic Stage I Non-Small Cell Lung Cancer Resection.
Harada H; Miyamoto K; Yamashita Y; Taniyama K; Ohdan H; Okada M
Ann Thorac Surg; 2015 May; 99(5):1746-54. PubMed ID: 25825198
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide combination profiling of DNA copy number and methylation for deciphering biomarkers in non-small cell lung cancer patients.
Son JW; Jeong KJ; Jean WS; Park SY; Jheon S; Cho HM; Park CG; Lee HY; Kang J
Cancer Lett; 2011 Dec; 311(1):29-37. PubMed ID: 21757291
[TBL] [Abstract][Full Text] [Related]
14. Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer.
Kim H; Kwon YM; Kim JS; Han J; Shim YM; Park J; Kim DH
Cancer; 2006 Sep; 107(5):1042-9. PubMed ID: 16888795
[TBL] [Abstract][Full Text] [Related]
15. HOXA9 methylation and blood vessel invasion in FFPE tissues for prognostic stratification of stage I lung adenocarcinoma patients.
Lissa D; Ishigame T; Noro R; Tucker MJ; Bliskovsky V; Shema S; Beck JA; Bowman ED; Harris CC; Robles AI
Lung Cancer; 2018 Aug; 122():151-159. PubMed ID: 30032824
[TBL] [Abstract][Full Text] [Related]
16. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer.
Hsu HS; Wen CK; Tang YA; Lin RK; Li WY; Hsu WH; Wang YC
Clin Cancer Res; 2005 Aug; 11(15):5410-6. PubMed ID: 16061855
[TBL] [Abstract][Full Text] [Related]
18. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer.
Kim DH; Kim JS; Ji YI; Shim YM; Kim H; Han J; Park J
Cancer Res; 2003 Jul; 63(13):3743-6. PubMed ID: 12839968
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of p16(INK4a) hypermethylation in non-small cell lung cancer is evident by quantitative DNA methylation analysis.
Ota N; Kawakami K; Okuda T; Takehara A; Hiranuma C; Oyama K; Ota Y; Oda M; Watanabe G
Anticancer Res; 2006; 26(5B):3729-32. PubMed ID: 17094392
[TBL] [Abstract][Full Text] [Related]
20. Identification of HERC5 and its potential role in NSCLC progression.
Wrage M; Hagmann W; Kemming D; Uzunoglu FG; Riethdorf S; Effenberger K; Westphal M; Lamszus K; Kim SZ; Becker N; Izbicki JR; Sandoval J; Esteller M; Pantel K; Risch A; Wikman H
Int J Cancer; 2015 May; 136(10):2264-72. PubMed ID: 25353388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
